Somatostatin Inhibition: How GHRPs Amplify GH Pulses

# Somatostatin Inhibition: How GHRPs Amplify GH Pulses

For Research Purposes Only -- Not Intended for Human or Animal Consumption

Growth hormone secretion is regulated by two opposing hypothalamic hormones: GHRH (stimulates GH release) and somatostatin (inhibits GH release). Understanding somatostatin's role is essential for understanding how GH secretagogues produce their effects.

Somatostatin: The GH Brake

Somatostatin is a cyclic 14-amino acid peptide produced by hypothalamic neurons in the periventricular nucleus. It binds to somatostatin receptors (SSTR1-5) on pituitary somatotrophs, inhibiting adenylyl cyclase and reducing cAMP levels. This opposes GHRH's stimulatory effects and reduces GH exocytosis.

Pulsatile GH secretion: GH pulses occur when GHRH release is high and somatostatin tone is low. The largest GH pulses occur during slow-wave sleep, when somatostatin tone is at its nadir.

How GHRPs Reduce Somatostatin Tone

GHRPs (Ipamorelin, GHRP-6, GHRP-2) stimulate GH release through two complementary mechanisms:

1. Direct pituitary effect: GHS-R1a activation on somatotrophs triggers IP3/calcium signaling, directly stimulating GH vesicle exocytosis
2. Hypothalamic somatostatin inhibition: GHS-R1a receptors on somatostatin neurons inhibit somatostatin release when activated by GHRPs, reducing the inhibitory tone on somatotrophs

This dual mechanism explains why GHRPs produce larger GH pulses than GHRH alone at equivalent doses.

The Synergy Between GHRH Analogues and GHRPs

The combination of CJC-1295 + Ipamorelin produces synergistic GH release: - GHRH analogue: cAMP/PKA pathway -> increases GH synthesis and sensitizes somatotrophs - GHRP: IP3/calcium pathway -> triggers GH exocytosis AND reduces somatostatin tone

Bowers et al. demonstrated that GHRH + GHRP-6 produced GH release 2-3 times greater than the sum of individual effects -- true synergy, not simple additivity.

References

1. Bowers, C.Y., et al. (1990). On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology, 114(5), 1537-1545.
2. Tannenbaum, G.S., & Ling, N. (1984). The interrelationship of GH-releasing factor and somatostatin. Endocrinology, 115(5), 1952-1957.
3. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.